TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2692894
Drug: Intra-articular methylprednisolone
Normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-articular methylprednisolone injection
Study: 31324040
Drug: Pectin supplementation
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin supplementation (15 g/day for four weeks)
Study: 30672196
Drug: Heat sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat sensitive moxibustion combined with articular injection of triamcinolone, 2 courses, 2 weeks as a course, 5 times a week.
Study: 30672196
Drug: Articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articular injection of triamcinolone, 2 courses, 2 times as a course, once every 5 days.
Study: 22460270
Drug: Docetaxel +
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel + Sunitinib (DS arm: docetaxel 60 mg m(‐2) every 3 weeks + sunitinib 37.5 mg every day)
Study: 22460270
Drug: Docetaxel only
Normalized name: Docetaxel only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel only (D only arm: 60 mg m(‐2), every 3 weeks)
Study: 1694714
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg + Terfenadine 180 mg
Study: 29160135
Drug: Dienogest therapy
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest therapy (P group)
Study: 29160135
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (C group)
Study: 26259627
Drug: hERG potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hERG potassium channel blocking drugs (Dofetilide and Moxifloxacin)
Study: 25194614
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299 v (5 × 10(9) cfu per capsule, 2 capsules daily for 8 weeks)
Study: 25194614
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules daily for 8 weeks)
Study: 25194614
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L. plantarum 299 v and placebo)
Study: 20472253
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.5 g of n‐3 long‐chain polyunsaturated fatty acid/day)
Study: 12909222
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of external beam radiotherapy (EBRT) and high-dose-rate intraluminal brachytherapy (ILBT) (Group 2)
Study: 12909222
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EBRT and ILBT (Group 2)
Study: 10318656
Drug: Eptifibatide (high-dose)
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide (high-dose)
Study: 1776336
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PGI2 and molsidomine
Study: 1776336
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of PGI2
Study: 1776336
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of molsidomine
Study: 6408274
Drug: Heparin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1000 units per liter)
Study: 31783862
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase supplementation with triptorelin (either as a single bolus or multiple injections)
Study: 29972000
Drug: Rehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation group (routine rehabilitation treatment)
Study: 26932144
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline administered intravenously)
Study: 20846441
Drug: Weekly 30-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 30-minute massage sessions
Study: 20846441
Drug: Massages plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massages plus stretching exercises performed twice a day
Study: 9243352
Drug: Oral selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selegiline (10 mg)
Study: 12077684
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PGl 2 and aprotinin
Study: 8749880
Drug: Disopyramide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (2 mg/kg)
Study: 2522723
Drug: Celiprolol (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200, 400, 600 mg/day)
Study: 30900658
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac sodium (100 mg twice daily)
Study: 27993667
Drug: Convective radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convective radiofrequency thermal therapy with the Rezūm® System
Study: 27993667
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rigid cystoscopy with simulated active treatment)
Study: 22807253
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + prednisone (10 mg of prednisone)
Study: 12932067
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with hyperbaric bupivacaine 0.5% 5 mg and fentanyl 25 microg
Study: 10720278
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of NGF
Study: 7886781
Drug: IVR 400
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVR 400 micrograms/kg plus DEC 6 mg/kg
Study: 30829679
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of lactoferrin and 0.2 g of lysozyme daily for 16 weeks
Study: 24294684
Drug: Specially processed
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specially processed cereal (SPC) treatment
Study: 21683053
Drug: Audio feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio feedback with cognitive preparation
Study: 15552536
Drug: Carbamazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (600 mg/day) added to fluphenazine (5-10 mg/day)
Study: 15552536
Drug: Sole fluphenazine
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole fluphenazine (5-10 mg/day)
Study: 9089819
Drug: No antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antipsychotic medications
Study: 1447391
Drug: Metronidazole 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 25% dental gel administered 1 x a week for 2 weeks
Study: 1447391
Drug: Metronidazole 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 15% dental gel applied 1 x a week for 2 weeks
Study: 1447391
Drug: Metronidazole 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 15% dental gel applied 2 x a week for 2 weeks
Study: 17910618
Drug: Indinavir combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir combined with low-dose ritonavir
Study: 17910618
Drug: Saquinavir combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir combined with low-dose ritonavir
Study: 17910618
Drug: Lopinavir combined
Normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir combined with low-dose ritonavir
Study: 15616073
Drug: Ketamine 10
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 10 mg
Study: 12391054
Drug: Naloxone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (30 mg iv bolus)
Study: 1789399
Drug: Budesonide powder
Normalized name: budesonide Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide powder 400 micrograms daily
Study: 1789399
Drug: Budesonide powder
Normalized name: budesonide Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide powder 800 micrograms daily
Study: 1789399
Drug: Budesonide aerosol
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aerosol 400 micrograms daily
Study: 28912191
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy administration (30 kcal/kg/day) starting within 24 hours of hospital admission
Study: 28912191
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy administration during the first 72 hours of hospital admission
Study: 21541815
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (38 diabetic patients on medical therapy)
Study: 18807128
Drug: omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 10 mg and 20 mg
Study: 11870241
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (400 mg oral daily)
Study: 2533450
Drug: High-dose MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MPA (100 mg/day)
Study: 2533450
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (Danazol and MPA)
Study: 19508712
Drug: Web-based self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based self-management programme for insulin titration
Study: 15365700
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HRT)
Study: 11875727
Drug: ALT (Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALT (Docetaxel 100 mg/m² plus FEC 75) alternated for eight courses
Study: 11875727
Drug: SEQ T
Normalized name: Selegiline
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SEQ T (Four courses of Docetaxel 100 mg/m² followed by four courses of FEC 75)
Study: 11875727
Drug: SEQ F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEQ F (Four courses of FEC 75 followed by four courses of Docetaxel 100 mg/m²)
Study: 10086937
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Synacthen test (LDST)
Study: 2193496
Drug: Lidoflazine 360
Normalized name: Lidoflazine
DrugBank: Lidoflazine (DB13766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine 360 mg daily
Study: 30959528
Drug: Group Treatment
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Treatment (GT)
Study: 30959528
Drug: Self-Administered Individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Administered Individual Treatment (SIT)
Study: 22782464
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic antibiotic administration
Study: 22782464
Drug: Extended prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended prophylactic antibiotic administration
Study: 17531921
Drug: Augmentation Index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation Index (AI)
Study: 15087948
Drug: Native Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native Escherichia coli asparaginase (9 doses during induction)
Study: 15087948
Drug: PEG-asparaginase (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-asparaginase (6 or 10 doses)
Study: 11840364
Drug: Typical dialysis
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical dialysis dose (equilibrated Kt/V = 1.30 +/- 0.22)
Study: 10920945
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy via implanted drug delivery system (DDS), administered once every 1 or 2 weeks (Group A)
Study: 10920945
Drug: One bolus
Normalized name: PHENYLBUTAZONE 1 g ORAL TABLET [Phenylbutazone Boluses]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One bolus arterial infusion chemotherapy, administered once every month (Group B)
Study: 2685707
Drug: Timolol treatment
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol treatment (TT)
Study: 790537
Drug: 0.5% chlorhexidine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% chlorhexidine-containing gel
Study: 28528348
Drug: Home oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home oxygen plus home NIV (median oxygen flow rate, 1.0 L/min; inspiratory positive airway pressure of 24 cm H2O; expiratory positive airway pressure of 4 cm H2O; backup rate of 14 breaths/minute)
Study: 28528348
Drug: Home oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home oxygen alone (median oxygen flow rate, 1.0 L/min)
Study: 12723055
Drug: Elman network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elman network for dosage prediction
Study: 11206597
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg daily for 12 weeks or 25 mg daily for 10 weeks)
Study: 8692558
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin
Study: 6647203
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral labetalol
Study: 6647203
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intramuscular hydralazine
Study: 30314978
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/d
Study: 23228503
Drug: AG200-15 Agile
Normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 Agile Patch applied to the lower abdomen
Study: 23228503
Drug: AG200-15 Agile
Normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 Agile Patch applied to the buttock
Study: 23228503
Drug: AG200-15 Agile
Normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 Agile Patch applied to the upper torso
Study: 23228503
Drug: AG200-15 Agile
Normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 Agile Patch (all sites)
Study: 20003064
Drug: Infant milk
Normalized name: Infant milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant milk formula supplemented with 6 g/l short‐chain galacto‐ and long‐chain fructo‐oligosaccharides (scGOS/lcFOS, ratio 9:1)
Study: 17030757
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist nontreated group (Control)
Study: 3690807
Drug: Single-agent metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent metoclopramide (2 mg/kg x 4)
Study: 3690807
Drug: Combination metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination metoclopramide and dexamethasone
Study: 31665898
Drug: PRP injection
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP injection into the muscle and skin layers immediately after wound closure
Study: 31665898
Drug: No PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PRP injection (Control)
Study: 29958267
Drug: Lenalidomide in
Normalized name: Product containing lenalidomide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide in combination with dexamethasone
Study: 29958267
Drug: Bortezomib in
Normalized name: bortezomib Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib in combination with dexamethasone
Study: 25247709
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose MQ (15 mg/kg)
Study: 19633693
Drug: Topical tranilast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tranilast and artificial tears (q.i.d.)
Study: 19633693
Drug: Topical artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical artificial tears, sodium hyaluronate, and vitamin A
Study: 17432645
Drug: Congrong Tongbian
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Congrong Tongbian Oral Liquid (control group)
Study: 16115944
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) combined with vaccinations using CEA-derived CAP-1 peptide with adjuvants (CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2, CAP-1/dSLIM/IL-2, CAP-1/IL-2) for three cycles followed by weekly vaccinations until progression of disease.
Study: 16115944
Drug: Vaccination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination treatment
Study: 8804877
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 20 mg/kg/day for 6 months
Study: 6142645
Drug: Prazosin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.5 mg three times a day, titrated to a maximum dose of 12 mg per day)
Study: 6142645
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg three times a day, titrated to a maximum dose of 120 mg per day)
Study: 25306749
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (comparison group)
Study: 23180157
Drug: HPV6/11/16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV6/11/16/18 vaccine
Study: 17371782
Drug: Generic simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic simvastatin 20-40 mg
Study: 6318545
Drug: Soy hulls
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy hulls (26 g daily)
Study: 6318545
Drug: Corn bran
Normalized name: CORN BRAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn bran (52 g daily)
Study: 6318545
Drug: Apple powder
Normalized name: Nutricia SHS Phlexy-10 Black Currant/Apple Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple powder (52 g daily)
Study: 25022824
Drug: Medication education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication education group (group I)
Study: 25022824
Drug: Medication education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication education with behavioral intervention group (group II)
Study: 20375696
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (pressure therapy + silicone gel sheeting)
Study: 20375696
Drug: Pressure therapy
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Therapy System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure therapy (PG)
Study: 20375696
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheeting (SGS)
Study: 8535536
Drug: Beta-receptor blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-receptor blockers and/or diuretics
Study: 8535536
Drug: Calcium antagonists,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists, alpha 1 blockers, and ACE inhibitors
Study: 2227079
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg rectally, administered one to three times daily for a mean period of 2.5 days)
Study: 2227079
Drug: Dipyrone (controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (controlled group, administered one to three times daily for a mean period of 2.5 days)
Study: 24983295
Drug: Modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint‐induced movement therapy (CIMT)
Study: 24983295
Drug: Hand‐arm bimanual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand‐arm bimanual intensive therapy (HABIT)
Study: 24654314
Drug: MP29-02 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP29-02 (1 spray/nostril bid)
Study: 24654314
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) nasal spray (2 sprays/nostril qd)
Study: 21271793
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg plus Ezetimibe 10 mg
Study: 19432566
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg) and Vitamin E (400 iu) daily until delivery
Study: 15257794
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg primaquine
Study: 11747872
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg LNG taken 12 h apart on day 10 of the cycle (Group A)
Study: 11747872
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg LNG at the time of serum LH surge (Group B)
Study: 11747872
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg LNG 48 h after positive detection of urinary LH (Group C)
Study: 11747872
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg LNG during late follicular phase (Group D)
Study: 8400610
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (CC)